Struma ovarii screening

Struma ovarii Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Struma ovarii from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
ECG
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Struma ovarii screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Struma ovarii screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Struma ovarii screening
CDC on Struma ovarii screening
Struma ovarii screening in the news
Blogs on Struma ovarii screening
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Struma ovarii screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is insufficient evidence to recommend routine screening for Struma ovarii.

Screening

• There is insufficient evidence to recommend routine screening for Struma ovarii.
• However, in cases of metastatic struma ovarii post total thyroidectomy along with radioiodine scanning and radioiodine ablation, the thyroglobulin levels must be monitored as a tumor marker, and diagnostic radioiodine scans should be done to screen for residual or recurrent disease.